This phase II trial studies how well the combination of dabrafenib and trametinib works after
radiation therapy in children and young adults with high grade glioma who have a genetic
change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells
and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells
by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their
growth. Giving dabrafenib with trametinib after radiation therapy may work better than
treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade
glioma.

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Albuquerque

University of New Mexico Cancer Center

Biospecimen Collection

Dabrafenib Mesylate

Lumbar Puncture

Magnetic Resonance Imaging

Radiation Therapy

Trametinib Dimethyl Sulfoxide

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo
as a preventive treatment for migraine, as measured by the reduction in the number of
migraine days per month.

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Albuquerque Clinical Trials, Inc.

BHV-3500 (zavegepant)

Placebo

A Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

This trial studies the side effects of radiation therapy followed by atezolizumab in treating
patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy
delivers smaller doses of radiation therapy over time and may kill more tumor cells and have
fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. The purpose of this study is to test the safety and effectiveness of
radiation therapy followed by atezolizumab and find out what side effects, if any, it has on
patient's non-small cell lung cancer.

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Atezolizumab

Hypofractionated Radiation Therapy

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention
in adults who suffer from six or more migraine days per month. The study will enroll 765
patients across approximately 64 sites in the United States, Canada and Australia. Study
subjects will be divided evenly across a low dose group, a high dose group and a placebo
group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the
Company's novel injection paradigm.

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Albuquerque Clinical Trials Inc - Clinedge - PPDS

ABP-450

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

The main purpose of this study is to assess the efficacy and safety of Tirzepatide
(LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

Lovelace Medical Center

Tirzepatide

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

The main purpose of study is to evaluate the safety and immunogenicity of different dose
levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and
CMV-seropositive female and male participants 9 to 15 years of age. In addition,mRNA-1647
will be evaluated in female participants 16 to 25 years as a comparator cohort.

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

MedPharmics, LLC. - Albuquerque - Platinum - PPDS

mRNA-1647

A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety,
and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

University of New Mexico (UNM), MS Specialty Clinic

IMU-838

Placebo matching IMU-838

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

The purpose of this study is to evaluate the efficacy and safety of two different doses of
MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD)
participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study
will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is
that at least one of the MK-2060 doses is superior to placebo in increasing the time to first
occurrence of AVG event.

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Renal Medicine Associates ( Site 0690)

MK-2060

A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis

The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly
called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy)
versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in
participants who are newly diagnosed with PAH and are at intermediate or high risk of disease
progression.

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

University of New Mexico, Health Sciences Center ( Site 1048)

Sotatercept

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

This study is done to find out whether the medicine, semaglutide, has a positive effect on
early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not
contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have
17 clinic visits and 1 phone call with the study doctor. The study includes various tests and
scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study
period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study
will be performed on a selection of sites based on their experience with CSF sampling and
willingness to participate in this sub-study. The endpoints related to this sub-study are
exploratory only.

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Novo Nordisk Investigational Site

Semaglutide

Placebo (semaglutide)

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)

Albuquerque, New Mexico

Albuquerque

< 0 mi

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

< 0 mi

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

< 0 mi

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

< 0 mi

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

< 0 mi

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

< 0 mi

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

< 0 mi

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

< 0 mi

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

< 0 mi

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

< 0 mi

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)